PDF(Pubmed)
Abstract：
BACKGROUND A blood cell saver, or autotransfusion system, is used to collect, wash, and return autologous blood collected from the surgical patient. This report describes a 55-year-old man who underwent combined mitral and aortic valve replacement surgery with cardiopulmonary bypass and had a successful outcome following intraoperative and postoperative autologous blood transfusion using a blood cell saver. CASE REPORT The patient did not accept blood transfusion for reasons of religious conscience and was in a critical condition, receiving palliative care. He needed combined mitral and aortic valve replacement surgery. The surgery was conducted using a cell saver (Sorin Xtra Autotransfusion System) in the intraoperative and postoperative periods for 24 h, to resolve this challenging case, from a technical and ethical point of view. The volume of red blood cells recovered intraoperatively was 1430 mL, with a hematocrit level of 40%, and 690 mL, with a hematocrit of 35%, in the postoperative period. Therefore, a significant volume of autologous blood was recovered. The autologous blood transfusion resulted in an excellent clinical outcome for the patient, who was discharged on the ninth postoperative day. CONCLUSIONS We can conclude that the use of a blood cell saver in cardiac surgery, in both intra- and postoperative periods, resulted in the maintenance of adequate hemoglobin and hematocrit levels, no infection postoperatively, and rapid and complete recovery of the patient. Thus, the use of the blood cell saver guaranteed the individual\'s autonomy to refuse blood products safely, with good clinical results, and without dependence on allogeneic blood transfusions.
摘要：
背景技术血细胞保护者,或者自体输血系统,用于收集，wash,并返回从手术患者收集的自体血液。该报告描述了一名55岁的男子，他在体外循环下接受了二尖瓣和主动脉瓣联合置换手术，并在术中和术后使用血细胞保护者进行自体输血后获得了成功的结果。个案报告病人因宗教良心原因不接受输血,病情危重,接受姑息治疗。他需要二尖瓣和主动脉瓣联合置换手术。手术在术中和术后使用细胞保存器（SorinXtra自体输血系统）进行24小时，为了解决这个具有挑战性的案件，从技术和伦理的角度来看。术中回收的红细胞体积为1430mL,血细胞比容水平为40%,和690毫升，血细胞比容为35%,在术后期间。因此,回收了大量的自体血液。自体输血为患者带来了极好的临床结果，他在术后第九天出院。结论我们可以得出结论，在心脏手术中使用血细胞保护者，在术中和术后期间，导致维持足够的血红蛋白和血细胞比容水平，术后无感染,患者迅速完全恢复。因此，血细胞保护者的使用保证了个人安全拒绝血液制品的自主权，具有良好的临床效果，并且不依赖同种异体输血。
